# Margaret E Macy

List of Publications by Year
in descending order



| 33 | 794 | 623734 | 526287 |
|---|---|---|---|
| papers | citations | 14 h-index | 27 g-index |

| 39 | 39 | 39 | 1640 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1â€“2 trial. Lancet Oncology, The, 2020, 21, 121-133. | 10.7 | 204 |
| 2 | Bevacizumab as Therapy for Radiation Necrosis in Four Children With Pontine Gliomas. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1148-1154. | 0.8 | 76 |
| 3 | A phase 1 study of the CXCR4 antagonist plerixafor in combination with highâ€dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigatorsâ€™ Consortium study (POE 10â€03). Pediatric Blood and Cancer, 2017, 64, e26414. | 1.5 | 57 |
| 4 | Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clinical Cancer Research, 2018, 24, 6142-6149. | 7.0 | 55 |
| 5 | Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.. Journal of Clinical Oncology, 2019, 37, 10009-10009. | 1.6 | 49 |
| 6 | Clinical and molecular characteristics of congenital glioblastoma. Neuro-Oncology, 2012, 14, 931-941. | 1.2 | 45 |
| 7 | Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro-Oncology, 2022, 24, 1776-1789. | 1.2 | 37 |
| 8 | Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Design, Development and Therapy, 2018, Volume 12, 3549-3561. | 4.3 | 35 |
| 9 | Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood and Cancer, 2018, 65, e27023. | 1.5 | 31 |
| 10 | Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discovery, 2021, 11, 545-559. | 9.4 | 25 |
| 11 | Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.. Journal of Clinical Oncology, 2020, 38, 10525-10525. | 1.6 | 24 |
| 12 | Experience with ponatinib in paediatric patients with leukaemia. British Journal of Haematology, 2020, 189, 363-368. | 2.5 | 21 |
| 13 | A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and highâ€grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatric Blood and Cancer, 2017, 64, e26621. | 1.5 | 17 |
| 14 | Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nature Medicine, 2022, 28, 1581-1589. | 30.7 | 16 |
| 15 | Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.. Journal of Clinical Oncology, 2020, 38, 107-107. | 1.6 | 15 |
| 16 | Bevacizumab in the treatment of radiation injury for children with central nervous system tumors. Child's Nervous System, 2019, 35, 2043-2046. | 1.1 | 11 |
| 17 | Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1<sup>+</sup> advanced, relapsed, or refractory solid tumor or lymphoma.. Journal of Clinical Oncology, 2017, 35, 10525-10525. | 1.6 | 11 |
| 18 | Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial. Cancer Immunology, Immunotherapy, 2022, 71, 2485-2495. | 4.2 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1â€“positive advanced, relapsed or refractory solid tumor or lymphoma.. Journal of Clinical Oncology, 2018, 36, 10525-10525. | 1.6 | 10 |
| 20 | Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.. Journal of Clinical Oncology, 2018, 36, 10536-10536. | 1.6 | 10 |
| 21 | A multiâ€center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatric Blood and Cancer, 2013, 60, 230-236. | 1.5 | 9 |
| 22 | Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precision Oncology, 2021, 5, 1840-1852. | 3.0 | 8 |
| 23 | A phase 1/2 doseâ€finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatric Blood and Cancer, 2018, 65, e27217. | 1.5 | 6 |
| 24 | Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles. Blood, 2020, 136, 30-31. | 1.4 | 4 |
| 25 | Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.. Journal of Clinical Oncology, 2021, 39, 10005-10005. | 1.6 | 2 |
| 26 | Phase I study of <sup>131</sup>I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.. Journal of Clinical Oncology, 2022, 40, 10038-10038. | 1.6 | 2 |
| 27 | Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.. Journal of Clinical Oncology, 2018, 36, 10541-10541. | 1.6 | 1 |
| 28 | A case of autoimmune hemolytic anemia with anti-D specificity in a 1-year-old child. Immunohematology, 2013, 29, 15-118. | 0.2 | 1 |
| 29 | Progression-free survival and patterns of response in patients with high-risk neuroblastoma (HR-NB) treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSFS) chemoimmunotherapy.. Journal of Clinical Oncology, 2022, 40, 10025-10025. | 1.6 | 1 |
| 30 | EAPH-14. MOLECULAR BIOLOGY AND PHASE I STUDY OF GM-CSF AND INTRATHECAL TRASTUZUMAB IN CHILDREN WITH RECURRENT POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 2018, 20, i68-i68. | 1.2 | 0 |
| 31 | EPCT-18. PHASE 0/I STUDY OF GM-CSF AND INTRATHECAL TRASTUZUMAB IN CHILDREN WITH RECURRENT POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 2020, 22, iii307-iii307. | 1.2 | 0 |
| 32 | EPEN-11. Phase 0/I Study of GM-CSF and Intrathecal Trastuzumab In Children With Recurrent Posterior Fossa Ependymoma. Neuro-Oncology, 2022, 24, i40-i40. | 1.2 | 0 |
| 33 | Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3Î²) inhibitor, alone or with irinotecan, temozolomide/irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results.. Journal of Clinical Oncology, 2022, 40, e22015-e22015. | 1.6 | 0 |